Adding L-Carnitine and Selenium to Methimazole in Graves’ Disease: A Prospective Randomized Trial on Thyroid Markers and Quality of Life
Nutrients · 20.08.2025 · 17 (16) · 2693
DOI: 10.3390/nu17162693 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, online erschienen am 20.08.2025. Verfasst von Mattia Rossi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, 10128 Turin, Italy. Hauptthemen laut MEDLINE: Methimazole, Graves Disease, Carnitine, Quality of Life. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The therapeutic response in Graves’ Disease (GD) remains largely unpredictable. Patients often experience persistent symptoms that are poorly correlated with thyroid hormone levels, an undefined treatment duration, and the need for long-term or definitive therapies. Based on the nuclear antagonistic properties of L-carnitine (LCT) on thyroid hormone action and the immunomodulatory role of selenium (Se), we aimed to assess the impact of adding a combined LCT and Se supplement to standard methimazole (MMI) therapy on the biochemical profile and quality of life (QoL) of patients with overt GD.
Methods
This multicenter prospective randomized trial enrolled 60 consecutive patients with newly diagnosed overt GD. Participants were randomized to receive either standard treatment with MMI alone (Control Group) or MMI plus the combined LCT/Se supplement (Intervention Group). TSH, fT3, fT4, and TSH–receptor antibodies (TRAb) levels were evaluated every two months for up to 24 months or until spontaneous remission or definitive therapy. At each visit, patients completed a symptom questionnaire addressing the frequency of typical thyrotoxic symptoms.
Results
No significant differences were observed between groups in the trend or time-to-normalization of TSH, fT3, and fT4 levels. However, the Intervention Group reached TRAb negativity significantly earlier (HR = 2.35 (1.14–4.81), p = 0.016), with a synergistic interaction with MMI therapy. MMI requirements were consistently lower in the Intervention Group, both in average dosage (p = 0.013) and cumulative dose (p = 0.020). The rate of spontaneous remission was significantly higher (OR = 11.22 (3.35–46.11), p < 0.001). Overall symptom burden did not differ significantly between groups; however, the supplement exerted an independent effect in reducing the severity of tremor, irritability, mood lability, heat intolerance, and exertional dyspnea.
Conclusions
Our findings suggest the clinical benefits of adding combined LCT and Se supplementation to MMI in the treatment of overt GD, including shorter disease duration, lower cumulative MMI exposure and earlier TRAb normality, that could positively influence TRAb-related prognostic outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, University of Turin, 10128 Turin, Italy.
- Endocrinology, Diabetology and Metabolism, AO "Ordine Mauriziano di Torino", 10128 Turin, Italy.
- Endocrinology, Department of Translational Medicine, University of Piemonte Orientale, 13100 Novara, Italy.
ORCID-Profile: Mattia Rossi, Loredana Pagano
Zitieren
APA
Rossi, M., Meomartino, L., Zavattaro, M., Selvatico, G., Rossetto Giaccherino, R., & Pagano, L. (2025). Adding L-Carnitine and Selenium to Methimazole in Graves’ Disease: A Prospective Randomized Trial on Thyroid Markers and Quality of Life. Nutrients, 17(16), 2693. https://doi.org/10.3390/nu17162693
Vancouver
Rossi M, Meomartino L, Zavattaro M, Selvatico G, Rossetto Giaccherino R, Pagano L. Adding L-Carnitine and Selenium to Methimazole in Graves’ Disease: A Prospective Randomized Trial on Thyroid Markers and Quality of Life. Nutrients. 2025;17(16):2693. doi:10.3390/nu17162693
BibTeX
@article{Rossi2025,
author = {Rossi, Mattia and Meomartino, Letizia and Zavattaro, Marco and Selvatico, Gloria and Rossetto Giaccherino, Ruth and Pagano, Loredana},
title = {Adding L-Carnitine and Selenium to Methimazole in Graves’ Disease: A Prospective Randomized Trial on Thyroid Markers and Quality of Life},
journal = {Nutrients},
year = {2025},
volume = {17},
number = {16},
pages = {2693},
doi = {10.3390/nu17162693}
}
EUVIMED